10 Firms Kick Off 2025 Trading in The Red

The stock market finished the first trading day of the year in the negative territory—a fifth straight day, over the lack of catalysts to spark trading appetite.

The Dow Jones Industrial Average was down the most by 0.36 percent, the S&P 500 decreased 0.22 percent, and the Nasdaq Composite dipped 0.16 percent.

Ten companies also kicked off trading mirroring the broader market downturn. In this article, let’s explore the reasons behind their decline.

To come up with Thursday’s top losers, we considered only the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.

A stock market graph. Photo by energepic.com

10. Aurora Innovation Inc. (NASDAQ:AUR)

Share prices of Aurora Innovation dropped for a fourth consecutive day on Thursday as investors continued to sell off positions over concerns that the US electric vehicle (EV) industry is now being dominated by Chinese EV makers.

Former Nissan executive Andy Palmer, often called the “Godfather of EVs,” recently told Business Insider that China is now the undisputed leader in EV manufacturing. The statement came as a stern warning to US and European automakers namely Tesla, GM, Volkswagen, and other EV makers which employ 4.3 million workers.

Investor sentiment was further dampened by news that sales of EV giant Tesla (NASDAQ: TSLA) fell for the first time in history, having only delivered 1.79 million vehicles during the year as compared with the 1.81 million in 2023, raising concerns about vehicle sales from other automakers such as GM.

9. Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA)

Shares of Teva Pharmaceuticals fell for a third day on Thursday, shedding another 3.34 percent or 0.74 points to finish at $21.3 apiece, as investors awaited further developments on its schizophrenia treatment Tev’749.

While the asset showed statistical improvement in schizophrenia symptoms during its Phase III trial, some experts raised concerns about the drug’s twice-daily dosing schedule, saying that the effectiveness of treatment often hinges on consistent medication, which can be particularly challenging for patients with schizophrenia.

In other news, the company recently made progress with its Duvakitug drug, developed with its French counterpart Sanofi, which met its primary goals of treating ulcerative colitis and Crohn’s disease.

Last year, the two firms announced a partnership to develop treatments for inflammatory bowel disease (IBD), with hopes that the drug could achieve a blockbuster status and generate at least $1 billion in annual sales.